Pay in 4 interest-free payments of $6.62 Learn more
Ships within 48 hours · Estimated delivery Aug 30 - Sep 4
Introduced Jan
GLP-1 receptor agonists have now received FDA approvals for cardiovascular risk reduction, obstructive sleep apnea, and chronic kidney disease, in addition to their original diabetes and obesity indications
doi: 10.1056/NEJMOA1607141/SUPPL_FILE/NEJMOA1607141_DISCLOSURES.PDF 15 HolmanRRBethelMAMentzRJThompsonVPLokhnyginaYBuseJBet al
Short-term metformin exposure increases TRPM6 activity, but long-term use leads to decreased TRPM6 gene expression and reduced magnesium uptake, resulting in lower plasma magnesium levels
Lancet 368:16961705 Meier JJ, Nauck MA (2004) The potential role of glucagon-like peptide 1 in diabetes
US$ 27.66
US$ 24.05
US$ 27.88
